Hetrombopag for Lower-risk MDS With Thrombocytopenia: a Prospective，Open-label, Single-arm Study.
Status:
Not yet recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
The is a phase 2, single-arm, open-label clinical study assessing the efficacy and safety of
hetrombopag to increase platelet count in lower-risk MDS patients with thrombocytopenia.